The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IPA | +326.07% | -89.63% | -36.44% | -60% |
| S&P | +15.66% | +86.6% | +13.29% | +205% |
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
No news articles found for MindWalk.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.97M | -33.7% |
| Gross Profit | $1.92M | -7.2% |
| Gross Margin | 64.55% | 18.4% |
| Market Cap | $86.31M | 625.7% |
| Market Cap / Employee | $846.22K | 0.0% |
| Employees | 102 | 1.0% |
| Net Income | -$2,319.61K | -24.1% |
| EBITDA | -$1,850.50K | -77.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.78M | 364.7% |
| Accounts Receivable | $2.89M | -20.1% |
| Inventory | 0.4 | -73.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.29M | -72.7% |
| Short Term Debt | $300.47K | -91.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.26% | -29.7% |
| Return On Invested Capital | -43.44% | -10.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,089.40K | -23.3% |
| Operating Free Cash Flow | -$2,038.08K | -23.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.60 | 1.16 | 4.48 | 5.75 | 950.51% |
| Price to Sales | 0.88 | 1.15 | 4.78 | 5.95 | 683.83% |
| Price to Tangible Book Value | 11.22 | 1.80 | 7.39 | 5.75 | -49.38% |
| Enterprise Value to EBITDA | -11.48 | -56.23 | -32.36 | -41.68 | 92.01% |
| Return on Equity | -121.7% | -102.7% | -110.9% | -121.8% | 83.09% |
| Total Debt | $8.93M | $9.70M | $2.69M | $2.59M | -78.03% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
